movfor
Movfor
Molnupiravir, an Oral Antiviral Treatment for COVID-19
Ingrédient actif: Molnupiravir
Disponibilité: disponible (14 packs)
Voir tout
Les autres noms de Movfor: 
Bexovid Covid Emorivir Favipiravir Lagevrio Molenzavir Molvir Monuvir Paxlovid Ritonavir 
Movfor 200mg
Nom du produitPour la piluleÉconomisezPar paquetCommande
40 bouchons€7.55€301.92Aujouter au panier
80 bouchons€6.37€94.35€603.84 €509.49Aujouter au panier
120 bouchons€5.98€188.70€905.76 €717.06Aujouter au panier
160 bouchons€5.78€283.05€1207.68 €924.63Aujouter au panier
200 bouchons€5.66€377.40€1509.60 €1132.20Aujouter au panier

  • Background

    Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

    Methods

    Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days. Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

    Results

    Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

    Conclusions

    Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.